AbBio, a biotech company in S.Korea, aims to develop a reliable adoptive cellular immunotherapy called as “sCAR-T” consisting of switch molecule and CAR-T which specifically recognizes the switch molecule.
Through a series of in vitro and in vivo studies, we have verified the mode of action of sCAR-T and confirmed the efficacy of sCAR-T against cancers. Building on these promising results, we are currently preparing for clinical trials to evaluate the therapy’s safety and effectiveness in humans.
By elaborately conducting clinical studies together with our partners, we will expedite the commercialization of our pipelines adopting sCAR-T to provide innovative and safe therapeutic modalities for patients suffering from devastating diseases such as cancer or autoimmune disease near future.
The biotech industry is undergoing a profound transformation, moving beyond conventional treatments to focus on true cures. This shift heralds a new era of precision medicine, with cancer immunotherapy playing a pivotal role in redefining patient outcomes.
In the past, centralized manufacturing systems emphasized standardized therapies designed for broad patient populations. Today, the paradigm has shifted toward precise diagnostics and the development of highly personalized therapies tailored to the unique health conditions of each individual.
Leveraging our proprietary technology, we are committed to delivering cutting-edge personalized cancer immunotherapies that demonstrate exceptional efficacy while minimizing adverse events. Through these groundbreaking efforts, we aim to set new standards in precision medicine, driving forward the future of transformative healthcare.
Our pursuit of personalized treatments is powered by the collective intelligence of academia, industry experts, healthcare providers, and patients. By serving as a platform for collaboration, we bring together diverse perspectives and expertise to fuel innovation and progress. Harnessing the strength of this shared knowledge and active participation, we aim to transform the future of medicine and deliver groundbreaking solutions that truly make a difference
| Company Name | AbBio Co., Ltd. |
|---|---|
| CEO | Myoung Ho Jeong |
| Establishment | March 10, 2021 |
| Head Office | #677, 1193, Jungang-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10414, Republic of Korea |
| Directors | Myoung Ho Jeong (C.E.O / Chairman of BoD) Sunjin Oh (Vice President) Yoonju Na (Director) |
|---|---|
| Auditor | Sang Baek Ha (C.E.O of Rhinos Asset Management Co., Ltd.) |
| Technology | Chief Science Advisor Koji Tamada M.D., Ph.D. |
|---|
“Anti-cancer immunotherapy, including adoptive cell therapies, has opened a new horizon in cancer treatment, with its therapeutic scope expanding from hematologic malignancies to solid tumors and autoimmune diseases.
AbBio’s innovative technology has the potential to overcome the current limitations of cancer immunotherapy, positioning itself as a next-generation solution poised to transform the existing paradigm of cancer treatment.”
